ClinicalTrials.gg
Active, not recruitingNCT03383458CheckMate 9DXUpdated Jul 31, 2026

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

A Phase 3 interventional study of Nivolumab and Placebo in Hepatocellular Carcinoma and Liver Cancer, sponsored by Bristol-Myers Squibb. Active, not recruiting at 184 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
545
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.

Enrollment
6th of 53
545 · median 40
Started
2018
with 7 others
Phase 3
4 of 53
none open now
Primary completion
2026-05
later than 4 of 16 live
Registered
11th of 53
by date
Lead sponsor
5 of 53
Bristol-Myers Squibb

Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 6th largest by enrollment, is one of 8 that started in 2018, is one of 4 in phase 3, reaches primary completion later than 4 of the 16 other live ones, and was the 11th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing nivolumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence

03

Conditions studied

  • Hepatocellular Carcinoma
  • Liver Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a first diagnosis of HCC who have undergone a curative resection or ablation
  • Participants are eligible to enroll if they have non-viral related-HCC, or if they have -HCC, or -HCC
  • Score 5 or 6
  • (ECOG) performance status (PS) 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Any evidence of tumor or co-existing malignant disease
  • Participants previously receiving any prior therapy for HCC, including loco-regional therapies
  • Participants who have undergone a liver transplant or those who are in the waiting list for liver transplantation
  • Participants who have received a live/attenuated vaccine within 30 days of randomization (eg, varicella, zoster, yellow fever, rotavirus, oral polio and measles, mumps, rubella [MMR]).

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
545 participants (actual)

Study arms

  • Experimental
    Arm A

    Biological: Nivolumab

  • Placebo comparator
    Arm B

    Other: Placebo

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • OtherPlacebo

    specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Recurrence-free Survival (RFS)

    Time frame: Up to 49 months

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 7 years

  2. Time to recurrence (TTR)

    Time frame: Up to 49 months

07

Study locations

184 sites
  • Local Institution - 0081
    Anniston, Alabama 36207, United States
  • Mayo Clinic in Arizona - Phoenix
    Phoenix, Arizona 85054, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85711, United States
  • Local Institution - 0135
    Los Angeles, California 90095, United States
  • Local Institution - 0088
    Palo Alto, California 94304, United States
  • Local Institution - 0085
    San Francisco, California 94115, United States
  • Local Institution - 0235
    Aurora, Colorado 80045, United States
  • Local Institution - 0267
    Miami, Florida 33125, United States
  • Sylvester Comprehensive Cancer Center/ UMHC
    Miami, Florida 33136, United States
  • Local Institution - 0163
    Tampa, Florida 33612, United States
  • Local Institution - 0009
    Atlanta, Georgia 30322, United States
  • Local Institution - 0025
    Westwood, Kansas 66205, United States
  • Local Institution - 0086
    New Orleans, Louisiana 70112, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • Local Institution - 0209
    St Louis, Missouri 63110, United States
  • Local Institution - 0075
    New York, New York 10016, United States
  • Local Institution - 0208
    New York, New York 10029, United States
  • Local Institution - 0045
    New York, New York 10065, United States
  • Local Institution - 0219
    White Plains, New York 10601, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Local Institution - 0206
    Portland, Oregon 97225, United States
  • Local Institution - 0272
    Austin, Texas 78705, United States
  • Local Institution - 0270
    Dallas, Texas 75246, United States
  • Local Institution - 0156
    Dallas, Texas 75390, United States
  • Local Institution - 0273
    Tyler, Texas 75702, United States
  • McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • Local Institution - 0154
    Seattle, Washington 98109, United States
  • Local Institution - 0243
    Gorriti, Buenos Aires 5737, Argentina
  • Local Institution - 0254
    Pilar, Buenos Aires 1629, Argentina
  • Local Institution - 0244
    Rosario, Santa Fe Province 2000, Argentina
  • Local Institution - 0239
    Blacktown, New South Wales 2148, Australia
  • Local Institution - 0166
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0141
    Concord, New South Wales 2139, Australia
  • Local Institution - 0220
    Herston, Queensland 4029, Australia
  • Local Institution - 0164
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0224
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0124
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0012
    Graz, 8036, Austria
  • Local Institution - 0003
    Vienna, 1090, Austria
  • Local Institution - 0001
    Vienna, 1100, Austria
  • Local Institution - 0033
    Brussels, 1070, Belgium
  • Local Institution - 0064
    Brussels, 1200, Belgium
  • Local Institution - 0068
    Edegem, 2650, Belgium
  • Local Institution - 0071
    Ghent, 9000, Belgium
  • Local Institution - 0108
    Leuven, 3000, Belgium
  • Local Institution - 0090
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0275
    Barretos, São Paulo 14780-070, Brazil
  • Local Institution - 0237
    Cerqueira César, São Paulo 01246-000, Brazil
  • Local Institution
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Local Institution
    São Paulo, São Paulo 08270-120, Brazil
  • Local Institution - 0023
    São Paulo, 01308-050, Brazil
  • Local Institution - 0236
    São Paulo, 01509-010, Brazil
  • Local Institution
    Calgary, Alberta T2N 4Z6, Canada
  • Local Institution - 0116
    Edmonton, T6G 1Z2, Canada
  • Local Institution - 0248
    Santiago, Santiago Metropolitan 0, Chile
  • Local Institution - 0246
    Santiago, Santiago Metropolitan 7710007, Chile
  • Local Institution - 0245
    Santiago, Santiago Metropolitan 8380420, Chile
  • Local Institution - 0247
    Viña del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0256
    Bogotá, 0, Colombia
  • Local Institution - 0057
    Bobigny, 93000, France
  • Local Institution - 0052
    Brest, 29200, France
  • CHU Estaing
    Clermont-Ferrand, 63003, France
  • Local Institution - 0046
    Clichy, 92110, France
  • Local Institution - 0061
    Créteil, 94010, France
  • Local Institution - 0013
    Grenoble, 38043, France
  • Local Institution - 0222
    Lille, 59037, France
  • Local Institution - 0051
    Lyon, 69317, France
  • Local Institution - 0043
    Montpellier, 34295, France
  • Local Institution - 0037
    Nice, 06202, France
  • Local Institution
    Poitiers, 86021, France
  • Local Institution - 0098
    Reims, 51100, France
  • Local Institution - 0212
    Rennes, 35033, France
  • Local Institution - 0044
    Saint-Priest-en-Jarez, 42270, France
  • Local Institution - 0011
    Vandœuvre-lès-Nancy, 54511, France
  • Local Institution - 0054
    Villejuif, 94800, France
  • Local Institution - 0024
    Aachen, 52057, Germany
  • Local Institution - 0258
    Berlin, 13353, Germany
  • Local Institution - 0020
    Bonn, 53127, Germany
  • Local Institution - 0050
    Cologne, 50937, Germany
  • Local Institution - 0026
    Essen, 45147, Germany
  • Local Institution - 0093
    Frankfurt am Main, 60590, Germany
  • Local Institution - 0040
    Hanover, 30625, Germany
  • Local Institution - 0019
    Homburg, 66421, Germany
  • Local Institution
    Leipzig, 04103, Germany
  • Local Institution - 0036
    Magdeburg, 39104 Magdeburg, Germany
  • Local Institution - 0048
    Mainz, 55131, Germany
  • Universitatsmedizin Mannheim
    Mannheim, 68167, Germany
  • Local Institution - 0096
    München, 81377, Germany
  • Local Institution - 0008
    Tübingen, 72076, Germany
  • Local Institution
    Würzburg, 97078, Germany
  • Local Institution - 0120
    Hong Kong, 999077, Hong Kong
  • Local Institution - 0076
    Hong Kong, Hong Kong
  • Local Institution - 0136
    Messina, ME 98125, Italy
  • Local Institution - 0102
    Bologna, 40138, Italy
  • Local Institution - 0077
    Florence, 50134, Italy
  • Local Institution - 0104
    Meldola, 47014, Italy
  • Local Institution - 0091
    Milan, 20133, Italy
  • Local Institution
    Modena, 41124, Italy
  • Local Institution - 0134
    Monserrato, 09042, Italy

Showing the first 100 of 184 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in May 2026, 97 months.

Of 52 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 97 months is above that.

Counting every sponsor, half of 138 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2017
First posted
Dec 26, 2017
StartActual
Apr 18, 2018
Primary completionActual
May 27, 2026
CompletionEst.
May 27, 2031
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03383458
Responsible party
Sponsor
First posted
Dec 26, 2017
Start date
Apr 18, 2018
Primary completion
May 27, 2026
Completion
May 27, 2031 (estimated)
Last update
Jul 31, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion